1. Go AS, Mozaffarian D, Roger VL, et al; American
Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke
statistics–2014 update: A report from the American
Heart Association. Circulation. 2014;129:e28-e292.
2. Boden WE, O’Rourke RA, Teo KK, et al; COURAGE
Trial Research Group. Optimal medical therapy with
or without PCI for stable coronary disease. N Engl J
Med. 2007;356( 15):1503-1516.
3. RITA- 2 trial participants. Coronary angioplasty
versus medical therapy for angina: The second
Randomised Intervention Treatment of Angina
(RITA- 2) trial. Lancet. 1997;350(9076):461-468.
4. Norton JL, Gibson DL. Establishing an outpatient
anticoagulation clinic in a community hospital. Am
J Health Syst Pharm. 1996;53( 10):1151-1157.
5. Morello CM, Zadvorny EB, Cording MA, Suemoto
RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics.
Am J Health Syst Pharm. 2006;63( 14):1325-1331.
6. Vivian EM. Improving blood pressure control in a
pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22( 12):1533-1540.
7. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ,
Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother.
2002; 36( 5):892-904.
8. Geber J, Parra D, Beckey NP, Korman L. Optimiz-
ing drug therapy in patients with cardiovascular
disease: The impact of pharmacist-managed phar-
macotherapy clinics in a primary care setting. Phar-
macotherapy. 2002; 22( 6):738-747.
9. Ranexa [package insert]. Foster City, CA: Gilead
Sciences, Inc.; 2013.
10. VHA Pharmacy Benefits Management Strategic
Healthcare Group and the Medical Advisory Panel.
Ranolazine. National PBM Drug Monograph. U.S.
Department of Veterans Affairs Pharmacy Benefits Management Services Website. http://www.pbm
.pdf. Published June 2007. Accessed May 7, 2014.
11. Fraker TD Jr, Fihn SD; writing on behalf of the
2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the
ACC/AHA 2002 guidelines for the management
of patients with chronic stable angina: A report
of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management
of patients with chronic stable angina. Circulation.
12. Funck-Brentano C, Jaillon P. Rate-corrected QT
interval: Techniques and limitations. Am J Cardiol.
13. Spertus JA, Winder JA, Dewhurst TA, et al. De-
velopment and evaluation of the Seattle Angina
Questionnaire: A new functional status measure
for coronary artery disease. J Am Coll Cardiol.
1995; 25( 2):333-341.
14. Drew BJ, Ackerman MJ, Funk M, et al; American
Heart Association Acute Cardiac Care Committee
of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American
College of Cardiology Foundation. Prevention of
torsade de pointes in hospital settings: A scientific
statement from the American Heart Association and
the American College of Cardiology Foundation.
Circulation. 2010;121( 8):1047-1060.
15. Heidenreich PA, McDonald KM, Hastie T, et al.
Meta-analysis of trials comparing beta-blockers,
calcium antagonists, and nitrates for stable angina.
JAMA. 1999;281( 20):1927-1936.
16. Chobanian AV, Bakris GL, Black HR, et al; National
Heart, Lung, and Blood Institute Joint National
Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure; National
High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint
National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure.
The JNC 7 report. JAMA. 2003;289( 19):2560-2572.
17. Reeder DN, Gillette MA, Franck AJ, Frohnapple DJ.
Clinical experience with ranolazine in a veteran
population with chronic stable angina. Ann Pharmacother. 2012; 46(1):42-50.
in HIV Management
NOW AVAILABLE in the App and Online
topics covered in this update include:
• Managing HIV Infection in the Health Care
Workplace: 30 Years Later
• Update on Integrase Strand Transfer Inhibitors
for the Treatment of HIV
• HIV and Hepatitis C Coinfection
• Care at the Crossroads: Navigating the HIV,
HCV, and Substance Abuse Syndemic
• Recent Advances in HIV Vaccine Development
With an Introduction by Jean-Louis Excler, MD
U.S. Military HIV Research Program (MHRP), Bethesda, Maryland
WWW.FEDPRAC.COM This special issue is supported by Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
and Salix Pharmaceuticals, Inc.